It is desirable to be able to non-invasively estimate the tissue blood oxygen saturation (rSO2) level in a human subject's brain. It is known that the cerebral tissue blood oxygen saturation level can be non-invasively estimated using near infrared spectrophotography (NIRS). A system and method for performing spatially resolved NIRS to measure cerebral tissue blood oxygen saturation (rSO2) was disclosed in U.S. Pat. No. 5,139,025, U.S. Pat. No. 5,482,034, and U.S. Pat. No. 5,217,013. In general, those patents describe calculating cerebral tissue blood oxygen saturation (rSO2) as a weighted sum of the venous [HbO2] and arterial [Hb] blood oxygen saturations according to the following equation: rSO2=[HbO2]/([HbO2]+[Hb]).
In the known system and method, a sensor having a light source and two light detectors, each spaced a different distance from the light source, is affixed to the forehead of a human subject. The light detector positioned closer to the source is referred to as the “near” or “shallow” detector and the light detector positioned further from the source is referred to as the “far” or “deep” detector. Light of three different wavelengths is selectively introduced into the subject's head, one wavelength at a time. The optical density (OD) of the reflected light of each wavelength is detected by both the “shallow” and the “deep” detectors. That data is used to calculate a so-called space contrasted ratio of the wavelength contrast difference according to the following equation:
OD′Deep-Shall(λ1)/OD′Deep-Shall(λ2)
where OD′ (λ)=OD (λ)−OD (λ+Δ) is the wavelength contrasted optical density that can be described as a wavelength contrast difference of the optical density OD (λ). In addition, ODDeep-Shall (λ)=ODDeep (λ)−ODShallow (λ) is the spatial contrasted optical density that is the difference of the optical density measured by the far detector ODDeep (λ) and the near detector ODShallow (λ) at wavelength λ. This space contrasted ratio of the wavelength contrast difference can be compared to empirical data to estimate the cerebral tissue blood saturation (rSO2) level of the human subject.
This approach is non-invasive and provides an accurate determination of the rSO2 level of most human subjects. However, it is has been observed that this approach results in invalid rSO2 estimations in approximately 1-2% of human subjects who have normal rSO2 levels, customarily referred to as “outliers.” For outliers, the above-described approach for estimating rSO2 results in a reported estimation that is significantly lower than the person's actual rSO2 level. There is evidence that melanin or a melanin-like (or melanin-based) polymer chromophore localized in the connective tissue that covers the brain may be responsible for outliers. While such polymers that are by products of tyrosine degradation are present in normal individuals, in individuals with alkaptonuria they accumulate excessively in the connective tissues. Depending on the amount of the melanin-like polymers in the brain membranes, the rSO2 baseline measured using thee wavelengths can be as low as 15%-20%, significantly less than the average normal rSO2 value of 70%. The presence of other chromophores may also be responsible for outliers.
Additionally, there is evidence that patients with liver disease can have a substantial amount of conjugated bilirubin present in their blood and tissues. While unconjugated bilirubin does not interfere with NIRS measurements, conjugated bilirubin preferentially absorbs in the 700 nm-770 nm range and can adversely affect accuracy of the above-described approach for estimating rSO2.
Accordingly, there is a need for an improved system and method for estimating cerebral tissue oxygen saturation (rSO2) levels in human subjects that is capable of identifying outliers and accurately estimating the cerebral tissue oxygen saturation levels for such outliers.
A system for assessing tissue blood oxygen saturation levels is disclosed. The system has a computing device and a sensor in communication with the computing device. The sensor is configured to be attached to a human subject and has a light source capable of selectively emitting at least four different wavelengths of light, one wavelength at a time. The sensor also has a first light detector positioned a first distance from said light source and a second light detector positioned a second distance from said light source, the second distance being greater than the first distance. The computing device has a memory for storing an algorithm and a processor for executing instructions associated with said algorithm.
The algorithm has the following steps. The light source emits light of at least four different wavelengths, one wavelength at a time, into a human subject. The computing device receives optical density measurements from said first and second light detectors for each of the four wavelengths. The computing device estimates a first tissue blood oxygen saturation value based on the optical density measurements associated with three of said four wavelengths. The computing device estimates a second tissue blood oxygen saturation value based the optical density measurements associated with four of said wavelengths. Finally, the computing device determines if said first tissue blood oxygen saturation value is a valid estimate of an actual tissue blood oxygen saturation level in said human subject based upon a comparison of said first tissue blood oxygen saturation value and said second blood oxygen saturation value.
When in use, the system 10 functions as described below, with reference to the illustrative flowchart in
Next (step 110 of
OD′Deep-Shall(λ1)/OD′Deep-Shall(λ2) (1)
where OD′ (λ)=OD (λ)−OD (λ+Δ) is the wavelength contrasted optical density that can be described as a wavelength contrast difference of the optical density OD (λ). In addition, ODDeep-Shall (λ)=ODDeep (λ)−ODShallow (λ) is the spatial contrasted optical density that is the difference of the optical density measured by the far detector ODDeep (λ) and the near detector ODShallow (λ) at wavelength λ. In the particular example given herein, OD′Deep-Shall (λ1)=[ODDeep (730)−ODShall (730)]−[ODDeep (770)−ODShall (770)] and OD′Deep-Shall (λ2)=[ODDeep (770)−ODshall (770)]−[ODDeep (810)−ODShall (810)]. The space contrasted ratio of OD′Deep-Shall (λ1)/OD′Deep-Shall (λ2) can be used according to methods known in the art to estimate the blood oxygen saturation (rSO2) value, by, for example, comparing the space contrasted ratio to empirical data correlating the space contrasted ratio to cerebral tissue blood oxygen saturation (rSO2) levels.
Next (step 120 of
OD″
Deep-Shall(λ)=ODDeep-Shall(λ+Δ)−2*ODDeep-Shall(λ)+ODDeep-Shall(λ−Δ) (2)
The second order contrasted optical density reflects the curvature of the optical density. In the particular example given herein, OD″Deep-Shall (730)=ODDeep-Shall (770)−2*ODDeep-Shall (730)+ODDeep-Shall (690).
OD″Deep-Shall(λ)/OD″Deep-Shall(λ+Δ) (3)
OD″Deep-Shall(λ)/OD′Deep-Shall(λ+Δ) (4)
Alternatively, the second order difference can be scaled using an empirical constant B, such as according to the following Equation 5:
OD″Deep-Shall(λ)/[ODDeep-Shall(λ+Δ)+B] (5)
Regardless of the method used (i.e., Equations (3), (4) or (5)), the resulting ratio is the second order contrasted optical density ratio. The second order contrasted optical density ratio is compared to empirical or modeled data of the second order contrasted optical density ratio to blood oxygen saturation (rSO2) to determine an estimated rSO2 of the human subject (step 125 of
Next (step 130 of
Next (at step 140 of
The second method involves an explicit use of the background spectra characteristic. The melanin and melanin-like compounds introduce the nonlinear background in the optical absorption spectra due to the exponential tail in the near-infrared band 700 nm-837 nm: OD melanin (λ)=C*exp (−λ/b) where b≈200 nm representing a variety of melanin-like polymers or other substances such as bilirubin with a long tail in the near infrared band, C is a constant that is proportional to the concentration and the path of light.
To remove the nonlinear background we can modify the contrasted value as:
OD″
Deep-Shall(λ)=[ODDeep-Shall(λ+Δ)−ODDeep-Shall(λ)]−A*[ODDeep-Shall(λ)−ODDeep-Shall(λ−Δ)]
Where A is the empirical constant specific for the melanin and melanin like compounds. The constant A reflects the relative difference between the background absorption in the (λ+Δ; λ) and (λ, λ−Δ) bands. It can be estimated as A=[exp(−Δ/b)−1]/[exp(+Δ/b)−1]. It may also include compensation for the wavelength dependence of the path of light if the coefficient A modified as follows:
A={DPF(λ+Δ/2)/DPF(λ−Δ/2)}*{[exp(−Δ/b)−1]/[exp(+Δ/b)−1]}
Where DPF (λ+Δ/2) is the differential path length factor (DPF), defined as the mean distance traveled by the photons divided by the distance between the points where light entered and left the head for the wavelength within interval [λ+Δ, λ]. The DPF (λ−Δ/2) is the differential path length factor (DPF) for the wavelength within interval [λ, λ−Δ]. The typical value of the DPF was found to linearly depend on the wavelength and to be within 7-4 for the wavelengths 690 nm-850 nm.
For the data on
For the data on
With regard to the processes, systems, methods, heuristics, etc. described herein, it should be understood that, although the steps of such processes, etc. have been described as occurring according to a certain ordered sequence, such processes could be practiced with the described steps performed in an order other than the order described herein. It further should be understood that certain steps could be performed simultaneously, that other steps could be added, or that certain steps described herein could be omitted. In other words, the descriptions of processes herein are provided for the purpose of illustrating certain embodiments, and should in no way be construed so as to limit the claims.
Accordingly, it is to be understood that the above description is intended to be illustrative and not restrictive. Many embodiments and applications other than the examples provided would be apparent upon reading the above description. The scope should be determined, not with reference to the above description, but should instead be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled. It is anticipated and intended that future developments will occur in the technologies discussed herein, and that the disclosed systems and methods will be incorporated into such future embodiments. In sum, it should be understood that the disclosure is capable of modification and variation.
All terms used in the claims are intended to be given their broadest reasonable constructions and their ordinary meanings as understood by those knowledgeable in the technologies described herein unless an explicit indication to the contrary in made herein. In particular, use of the singular articles such as “a,” “the,” “said,” etc. should be read to recite one or more of the indicated elements unless a claim recites an explicit limitation to the contrary.
This Application claims the benefit of U.S. Provisional application No. 61/307,175 filed on Feb. 23, 2010 and U.S. Provisional Application No. 61/317,795 filed on Mar. 26, 2010, the entirety of which are hereby incorporated by reference.
Number | Date | Country | |
---|---|---|---|
61307175 | Feb 2010 | US | |
61317795 | Mar 2010 | US |